Oral low-dose chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during pregnancy.

Abstract

We report for the first time the impact of neoadjuvant oral low-dose chemotherapy consisting of oral trofosfamide, idarubicin, and etoposide (O-TIE) in the case of alveolar rhabdomyosarcoma (RMS) in the lower jaw of an 18-year-old woman at 27 weeks of gestation, without fetal complications and a highly efficient anti-tumor response. Our study suggests the possible application of O-TIE treatment in a neoadjuvant setting during pregnancy and recommends a schedule that can be considered for the treatment of patients with high-risk sarcomas who cannot be treated with intensive chemotherapy for various reasons.

• Authors: Meinolf Siepermann, Ewa Koscielniak, Tobias Dantonello, Dirk Klee, Joachim Boos, Barbara Krefeld, Arndt Borkhardt, Thomas Hoehn, Alexzander Asea, Rüdiger Wessalowski
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 58 Issue 1 Pg. 104-6 (Jan 2012) ISSN: 1545-5017 [Electronic] United States
• PMID: 22076833 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Wiley Periodicals, Inc.

Chemical References

• Etoposide
• Cyclophosphamide
• trofosfamide
• Idarubicin

Topics

• Administration, Oral
• Adolescent
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (administration & dosage, analogs & derivatives)
• Dose-Response Relationship, Drug
• Etoposide (administration & dosage)
• Female
• Humans
• Idarubicin (administration & dosage)
• Pregnancy
• Pregnancy Complications, Neoplastic (drug therapy)
• Prognosis
• Rhabdomyosarcoma, Alveolar (drug therapy)